Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RNA Interference Drug Fitusiran Effective in both Hemophilia A and B

Publish date:: August 7, 2019

Key clinical point: The RNA interference drug fitusiran appears to be safe and efficacious in hemophilia A and B.

Major finding: Once-monthly fitusiran therapy was associated with a reduction in median annualized bleeding rates from 42.00 to 1.04 in patients with inhibitors.

Study details: A phase 2, open-label extension study in 34 individuals with hemophilia A and B, with and without inhibitors, who were treated with fitusiran for at least 2 years.

Disclosures: The study was funded by Sanofi Genzyme and Alnylam Pharmaceuticals, and six authors were employees of Sanofi Genzyme. Dr. Pasi reported financial relationships with pharmaceutical companies, including Alnylam.

Citation:

Pasi J et al. 2019 ISTH Congress, Abstract OC 11.3.

This Week's Must Reads

New evidence further supports starting CRC screening at age 45,

PT-Cy bests conventional GVHD prophylaxis,

Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL,

Adjuvant denosumab falls short in early-stage breast cancer,

Single-Fraction Spine Stereotactic Radiosurgery is Cost-Efficient,

Must Reads in Bleeding Disorders

Fibrinogen Concentrate Effective, Safe for Postop Bleeding,

Updated International Consensus Recommendations on Management of Acute Upper GI Bleeding,

Global Blood Supply Runs Low,

Emicizumab Effective in Children With Hemophilia A and Inhibitors,

ISTH Releases Draft Guideline for TTP Diagnosis, Treatment,